FRT vs ORGO · rev $1.28B vs rev $81.0M
FRT (FRT) versus Organogenesis Holdings Inc (ORGO) — a side-by-side from cached financials, not a winner call.
FRT (FRT) common stock.
Organogenesis Holdings Inc (ORGO) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Latest reported FRT revenue for 2025-12-31 was $1.28B. Net income was $411.1M. Revenue was up 6.4% from 2024-12-31 to 2025-12-31. FRT currently screens at market cap $0.
Latest reported ORGO revenue for 2026-06-30 was $81.0M. Net income was -$149.4M. ORGO currently screens at market cap $301.1M.
FRT currently screens at market cap $0. ORGO currently screens at market cap $301.1M.
Not investment advice. Open the FRT and ORGO stock pages for the full models.
Not investment advice.